期刊文献+

Alphabet strategy for diabetes care:A checklist approach in the time of COVID-19 and beyond

下载PDF
导出
摘要 Chronic disease management requires achievement of critical individualised targets to mitigate again long-term morbidity and premature mortality associated with diabetes mellitus.The responsibility for this lies with both the patient and health care professionals.Care plans have been introduced in many healthcare settings to provide a patient-centred approach that is both evidence-based to deliver positive clinical outcomes and allow individualised care.The Alphabet strategy(AS) for diabetes is based around such a care plan and has been evidenced to deliver high clinical standards in both well-resourced and underresourced settings.Additional patient educational resources include special care plans for those people with diabetes undertaking fasting during Ramadan,Preconception Care, Prevention and Remission of Diabetes.The Strategy and Care Plan has facilitated evidence-based,cost-efficient multifactorial intervention with an improvement in the National Diabetes Audit targets for blood pressure,cholesterol levels and glycated haemoglobin.Many of these attainments were of the standard seen in intensively treated cohorts of key randomized controlled trials in diabetes care such as the Steno-2 and United Kingdom Prospective Diabetes Study.This is despite working in a relatively under-resourced service within the United Kingdom National Health Service.The AS for diabetes care is a useful tool to consider for planning care, education of people with diabetes and healthcare professional.During the time of the coronavirus disease 2019 pandemic the risk factors for the increased mortality observed have to be addressed aggressively.The AS has the potential to help with this aspiration.
出处 《World Journal of Diabetes》 SCIE 2021年第4期407-419,共13页 世界糖尿病杂志(英文版)(电子版)
  • 相关文献

参考文献1

二级参考文献20

  • 1Zimmet P, Alberti KG, Shaw J. Global and societal implications ofthe diabetes epidemic. Nature 2001; 414: 782-787 [PMID: 11742409DOI: 10.1038/414782a].
  • 2Mathers CD, Loncar D. Projections of global mortality and burdenof disease from 2002 to 2030. PLoS Med 2006; 3: e442 [PMID:17132052 DOI: 10.1371/journal.pmed.0030442].
  • 3Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating thecurrent and future costs of Type 1 and Type 2 diabetes in the UK,including direct health costs and indirect societal and productivitycosts. Diabet Med 2012; 29: 855-862 [PMID: 22537247 DOI:10.1111/j.1464-5491.2012.03698.x].
  • 4National Diabetes Audit 2011-2012. Report 1: Care Processes andTreatment Targets. Available from: URL: http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/nationaldiabetes-audit.
  • 5Lee JD, Saravanan P, Varadhan L, Morrissey JR, Patel V. Qualityof diabetes care worldwide and feasibility of implementation ofthe Alphabet Strategy: GAIA project (Global Alphabet StrategyImplementation Audit). BMC Health Serv Res 2014; 14: 467 [PMID:25306156 DOI: 10.1186/1472-6963-14-467].
  • 6Department of Health. National Service Framework for CoronaryArtery Disease. Mod-ern Standards and Service Models. London:Department of Health, 2000. Available from: URL: http://www.gov.uk/government/publications/quality-standards-for-coronary-heartdisease-care.
  • 7Patel V, Morrissey J. The Alphabet Strategy: the ABC of reducingdiabetes complications. Br J Diabetes Vasc Dis 2002; 2: 58-59.Available from: URL: http://dvd.sagepub.com/content/2/1/58.full.pdf.
  • 8UK Prospective Diabetes Study (UKPDS) Group. Intensiveblood-glucose control with sulphonylureas or insulin comparedwith conventional treatment and risk of complications in patientswith type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study(UKPDS) Group. Lancet 1998; 352: 837-853 [PMID: 9742976 DOI:10.1016/S0140-6736(98)07019-6].
  • 9UK Prospective Diabetes Study Group. Tight blood pressurecontrol and risk of macrovascular and microvascular complicationsin type 2 diabetes: UKPDS 38. UK Prospective Diabetes StudyGroup. BMJ 1998; 317: 703-713 [PMID: 9732337 DOI: 10.1136/bmj.317.7160.703].
  • 10Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, NeilHA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-MenysV, Fuller JH. Primary prevention of cardiovascular disease withatorvastatin in type 2 diabetes in the Collaborative AtorvastatinDiabetes Study (CARDS): multicentre randomised placebocontrolledtrial. Lancet 2004; 364: 685-696 [PMID: 15325833 DOI:10.1016/S0140-6736(04)16895-5].

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部